Septerna (SEPN) Stock

Profile

Full Name:

Septerna, Inc.

Sector:

Healthcare

Industry:

Biotechnology

Country:

United States

IPO:

Indexes:

Not included

Description:

Septerna is a biotechnology company focused on developing innovative therapies for diseases by harnessing the power of G protein-coupled receptors (GPCRs) to create new treatment options.

Events Calendar

Earnings

Next earnings date:

N/A

Recent quarterly earnings:

N/A

Recent annual earnings:

N/A
Dividend

Next ex-dividend date:

N/A

Recent ex-dividend date:

N/A
Splits

Next split:

N/A

Recent split:

N/A

Analyst ratings

Recent major analysts updates

19 Nov '24 Wells Fargo
Overweight
19 Nov '24 TD Cowen
Buy
19 Nov '24 JP Morgan
Overweight
19 Nov '24 Cantor Fitzgerald
Overweight

Market Data

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Dividend

Profitability

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Efficiency

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Valuation

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Liquidity

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Cash Flow

Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
series name
Suggested series

Institutional Ownership

Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
Septerna Announces Closing of $331.2 Million Upsized Initial Public Offering
SEPN
globenewswire.com30 October 2024

SOUTH SAN FRANCISCO, Calif., Oct. 30, 2024 (GLOBE NEWSWIRE) -- Septerna, Inc. (Nasdaq: SEPN), a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery, today announced the closing of its upsized initial public offering (IPO) of 18,400,000 shares of its common stock at a public offering price of $18.00 per share, which includes an additional 2,400,000 shares issued upon the full exercise by the underwriters of their option to purchase additional shares. All of the shares were offered by Septerna.

FAQ

  • What is the primary business of Septerna?
  • What is the ticker symbol for Septerna?
  • Does Septerna pay dividends?
  • What sector is Septerna in?
  • What industry is Septerna in?
  • What country is Septerna based in?
  • Is Septerna in the S&P 500?
  • Is Septerna in the NASDAQ 100?
  • Is Septerna in the Dow Jones?
  • When does Septerna report earnings?
  • Should I buy Septerna stock now?

What is the primary business of Septerna?

Septerna is a biotechnology company focused on developing innovative therapies for diseases by harnessing the power of G protein-coupled receptors (GPCRs) to create new treatment options.

What is the ticker symbol for Septerna?

The ticker symbol for Septerna is NASDAQ:SEPN

Does Septerna pay dividends?

No, Septerna does not pay dividends

What sector is Septerna in?

Septerna is in the Healthcare sector

What industry is Septerna in?

Septerna is in the Biotechnology industry

What country is Septerna based in?

Septerna is headquartered in United States

Is Septerna in the S&P 500?

No, Septerna is not included in the S&P 500 index

Is Septerna in the NASDAQ 100?

No, Septerna is not included in the NASDAQ 100 index

Is Septerna in the Dow Jones?

No, Septerna is not included in the Dow Jones index

When does Septerna report earnings?

The date for Septerna's next earnings report has not been announced yet

Should I buy Septerna stock now?

As of today, analysts generally recommend a 'Strong buy' rating. However, it's important to do your own research and consider your financial situation before making any investment decisions